Abstract:Background A subgroup of myocarditis can lead to heart failure. However, whether prognosis of myocarditis-induced heart failure differs from other heart failure remains largely unknown. Aim This study aimed to investigate the prognostic impact of myocarditis induced heart failure compared with heart failure with dilated cardiomyopathy and ischaemic heart disease as causes respectively in the overall population and a propensity score-matched cohort, based on patient-level data from the Swedish Heart Failure Registry (SwedeHF). Methods Patients with heart failure (HF) were enrolled from the SwedeHF (2003-2020) linked with the National Patient Register, and the Swedish Cause of Death Register. Endpoints were all-cause mortality, cardiovascular death, and hospital re-admissions, followed up from the index date until censoring or event. Results Of 54416 patients identified through the SwedeHF with HF, 418 hade myocarditis as aetiology (MC-HF), 6,871 with dilated cardiomyopathy (DCM-HF) and 47127 with ischemic heart diseases (IHD-HF). In general patients with MC-HF have shorter disease duration and less comorbidities compared with DCM-HF and IHD-HF, but older than DCM-HF and younger than IHD-HF. Compared with DCM-HF, MC-HF are associated with 29% higher risk for all cause mortality [(1.29 (1.07 - 1.55), p=0.0079] and 40% higher risk for cardiovascular death [ 1.40 (1.09 - 1.80), p=0.0088], and 19 % higher risk for heart failure rehospitalization [1.19 (1.03 - 1.37), p=0.018] and even higher risk by censoring within one-year . However, compared with IHD-HF, patients with MC-HF have similar risk for all cause mortality [0.95 (0.80 - 1.13), p=0.54], cardiovascular death [0.95 (0.75 - 1.20), p=0.65], and heart failure rehospitalization [0.93 (0.81 - 1.06), p=0.29]. Similar results were obtained from a propensity 1:2 matched cohort. No significant interactions were found regardless of age (< and < 70 years) , sex, LVEF (≥50%, 40-49%, 30-39% and < 30%) for all cause mortality comparing MC-HF vs DCM-HF, and MC-HF vs IHD-HF. Conclusion Patients with myocarditis-induced heart failure have worse outcome than heart failure due to dilated cardiomyopathy, with even higher risk during one year. This finding highlights the importance of early and more effective customized management of patients with myocarditis in particular those with high risk to develope heart failure.

Ischemic Cardiomyopathy versus Non-Ischemic Dilated Cardiomyopathy in Patients with Reduced Ejection Fraction— Clinical Characteristics and Prognosis Depending on Heart Failure Etiology (Data from European Society of Cardiology Heart Failure Registries)

Different Clinical Features, Biochemical Profiles, Echocardiographic and Elctrocardiographic Findings in Older and Younger Patients with Idiopathic Dilated Cardiomyopathy

Clinical characteristics, treatment, trajectories and outcome of patients with dilated cardiomyopathy in a national heart failure registry

Clinical Characteristics, Treatment and Prognosis of Patients with Idiopathic Dilated Cardiomyopathy: a Tertiary Center Experience

Distribution and prognostic impact of different heart failure etiologies in patients with heart failure with mildly reduced ejection fraction

Prognostic value of multiple cardiac magnetic resonance imaging parameters in patients with idiopathic dilated cardiomyopathy

Cardiac Resynchronization Therapy with Defibrillator in Ischemic Versus Nonischemic Cardiomyopathy

Ischemic cardiomyopathy: epidemiology, pathophysiology, outcomes, and therapeutic options

Comparing outcomes in cardiogenic shock patients with ischemic versus nonischemic cardiomyopathy: A nationwide retrospective observational study

Ischemic heart failure versus non ischemic heart failure is there differences?

Differences between familial and sporadic dilated cardiomyopathy: ESC EORP Cardiomyopathy & Myocarditis registry

Prognostic impact of myocarditis as aetiology compared with dilated cardiomyopathy and ischaemic heart disease in heart failure

Non‐dilated left ventricular cardiomyopathy vs. dilated cardiomyopathy: clinical background and outcomes

Inflammation-Related Biomarkers Are Associated with Heart Failure Severity and Poor Clinical Outcomes in Patients with Non-Ischemic Dilated Cardiomyopathy

Distinct Circulating Expression Profiles of Long Noncoding RNAs in Heart Failure Patients with Ischemic and Nonischemic Dilated Cardiomyopathy.

Abstract 11983: Prolonged Coronary Arterial Phase and Recurrent Ischemia Are Hallmarks of Repeat Heart Failure and Sudden Cardiac Death in Patient with Dilated Cardiomyopathy and Patent Coronary Arteries an Angiographic and Machine Learning Analysis

Sex-based differences in the phenotypic expression and prognosis of idiopathic non-ischaemic cardiomyopathy: a cardiovascular magnetic resonance study

Comparison of the Benefit of Primary Prevention Implantable Cardioverter-Defibrillator Therapy in Ischemic Versus Nonischemic Dilated Cardiomyopathy

Clinical analysis of 280 patients with dilated cardiomyopathy

Clinical determinants of mortality in chronic congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy

Efficacy of Beta-Blockers and Angiotensin-Converting Enzyme Inhibitors in Non-Ischemic Dilated Cardiomyopathy: A Systematic Review and Meta-Analysis